Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, 660 S. Euclid Ave, St. Louis, MO, 63110, USA.
Mol Neurodegener. 2022 Feb 2;17(1):13. doi: 10.1186/s13024-022-00516-0.
One of the key pathological hallmarks of Alzheimer disease (AD) is the accumulation of the amyloid-β (Aβ) peptide into amyloid plaques. The apolipoprotein E (APOE) gene is the strongest genetic risk factor for late-onset AD and has been shown to influence the accumulation of Aβ in the brain in an isoform-dependent manner. ApoE can be produced by different cell types in the brain, with astrocytes being the largest producer of apoE, although reactive microglia also express high levels of apoE. While studies have shown that altering apoE levels in the brain can influence the development of Aβ plaque pathology, it is not fully known how apoE produced by specific cell types, such as astrocytes, contributes to amyloid pathology.
We utilized APOE knock-in mice capable of having APOE selectively removed from astrocytes in a tamoxifen-inducible manner and crossed them with the APP/PS1-21 mouse model of amyloidosis. We analyzed the changes to Aβ plaque levels and assessed the impact on cellular responses to Aβ plaques when astrocytic APOE is removed.
Tamoxifen administration was capable of strongly reducing apoE levels in the brain by markedly reducing astrocyte apoE, while microglial apoE expression remained. Reduction of astrocytic apoE3 and apoE4 led to a large decrease in Aβ plaque deposition and less compact plaques. While overall Iba1 microglia were unchanged in the cortex after reducing astrocyte apoE, the expression of the disease-associated microglial markers Clec7a and apoE were lower around amyloid plaques, indicating decreased microglial activation. Additionally, astrocyte GFAP levels are unchanged around amyloid plaques, but overall GFAP levels are reduced in the cortex of female apoE4 mice after a reduction in astrocytic apoE. Finally, while the amount of neuritic dystrophy around remaining individual plaques was increased with the removal of astrocytic apoE, the overall amount of cortical amyloid-associated neuritic dystrophy was significantly decreased.
This study reveals an important role of astrocytic apoE3 and apoE4 on the deposition and accumulation of Aβ plaques as well as on certain Aβ-associated downstream effects.
阿尔茨海默病(AD)的一个关键病理学特征是淀粉样β(Aβ)肽积累成淀粉样斑块。载脂蛋白 E(APOE)基因是晚发性 AD 的最强遗传风险因素,并且已被证明以依赖于异构体的方式影响大脑中 Aβ的积累。APOE 可以由大脑中的不同细胞类型产生,星形胶质细胞是 APOE 的最大产生者,尽管反应性小胶质细胞也表达高水平的 APOE。虽然研究表明改变大脑中的 APOE 水平可以影响 Aβ斑块病理学的发展,但尚不完全清楚星形胶质细胞等特定细胞类型产生的 APOE 如何导致淀粉样病理学。
我们利用了能够以他莫昔芬诱导的方式选择性地从星形胶质细胞中去除 APOE 的 APOE 基因敲入小鼠,并将其与 APP/PS1-21 淀粉样变性小鼠模型进行了杂交。我们分析了 Aβ斑块水平的变化,并评估了当去除星形胶质细胞 APOE 时对细胞对 Aβ斑块的反应的影响。
他莫昔芬给药能够通过显著降低星形胶质细胞 APOE 强烈降低大脑中的 APOE 水平,而小胶质细胞 APOE 表达保持不变。减少 APOE3 和 APOE4 导致 Aβ斑块沉积大量减少和斑块不那么致密。虽然在减少星形胶质细胞 APOE 后大脑皮层中的总体 Iba1 小胶质细胞没有变化,但在淀粉样斑块周围,疾病相关的小胶质细胞标志物 Clec7a 和 APOE 的表达较低,表明小胶质细胞激活减少。此外,星形胶质细胞 GFAP 水平在淀粉样斑块周围保持不变,但在减少星形胶质细胞 APOE 后,雌性 APOE4 小鼠大脑皮层中的总体 GFAP 水平降低。最后,虽然在用星形胶质细胞 APOE 去除后,剩余的单个斑块周围的神经突性营养不良的量增加,但大脑皮层中与 Aβ相关的神经突性营养不良的总量显著减少。
这项研究揭示了星形胶质细胞 APOE3 和 APOE4 在 Aβ斑块的沉积和积累以及某些 Aβ 相关下游效应中的重要作用。